Diagnostic role of tests for T cell receptor (TCR) genes

E Hodges, M T Krishna, C Pickard, J L Smith

Rapid advances in molecular biological techniques have made it possible to study disease pathogenesis at a genomic level. T cell receptor (TCR) gene rearrangement is an important event in T cell ontogeny that enables T cells to recognise antigens specifically, and any dysregulation in this complex yet highly regulated process may result in disease. Using techniques such as Southern blot hybridisation, polymerase chain reaction, and flow cytometry it has been possible to characterise T cell proliferations in malignancy and in diseases where T cells have been implicated in the pathogenesis. The main aim of this article is to discuss briefly the process of TCR gene rearrangement and highlight the disorders in which expansions or clonal proliferations of T cells have been recognised. It will also describe various methods that are currently used to study T cell populations in body fluids and tissue, their diagnostic role, and current limitations of the methodology.

The T cell receptor (TCR) is a membrane bound heterodimer composed of two polypeptide chains (αβ or γδ) linked by a disulphide bond and associated with a non-polymorphic cytoplasmic membrane bound complex of proteins collectively known as CD3. In the peripheral blood, most T cells express the αβ receptor and up to 15% express the γδ receptor. The extracellular domains of the TCR consist of a constant (C) domain and a variable (V) domain. Hypervariable regions or complementarity determining regions (CDR) encoded within the TCR V domains contact the peptide antigen and the major histocompatibility (MHC) molecules and therefore confer the specificity of the TCR. Furthermore, T cells are MHC restricted in that CD4 positive or helper T cells recognise peptides bound to MHC class II molecules and CD8 positive or suppressor T cells recognise peptides bound to MHC class I molecules.

THE TCR LOCI

The TCR genes are located on chromosomes 7 and 14. The genes encoding the TCRα (TCRA) chain are located within the TCRα (TCRA) loci on chromosome 14q11–12, whereas the TCRβ (TCRB) and TCRγ (TCRG) genes are located at chromosomal positions 7q32–35 and 7p15, respectively (fig 1; table 1). The four genes are composed of C and V regions which are assembled together during thymic ontogeny by somatic recombination. Briefly, the V domains in the TCRα and TCRγ chains are assembled from V and J gene segments whereas the TCRβ and TCRδ chains are assembled from V, diversity (D), and J segments. The multiple non-contiguous V, D, and J segments undergo rearrangement during T cell development to form complete V domain exons, which are responsible for antigen recognition. Diversity of the T cell repertoire is not only a consequence of different V, D, J recombinations but also results from nucleotide insertion and deletion at junctional sites (V–J, D–J, and V–D), thereby increasing diversity for recognition of a vast array of antigens.

"The multiple non-contiguous V, D, and J segments undergo rearrangement during T cell development to form complete V domain exons, which are responsible for antigen recognition"

The TCRα genes consist of 70 V gene segments, divided into 41 families and at least 61 J segments spread over 800 kb upstream from a single C gene. The 61 J gene segments, consisting of 50 functional J genes, are not clustered and are located at over 65 kb at various distances 5' of the C gene. The TCRβ locus comprises approximately 67 V genes of which 47 are functional and 19 are pseudogenes. The functional TCRβV genes are grouped into 23 families based upon greater than 75% nucleotide sequence identity. Two C genes are associated with upstream clusters of J genes and a single D gene (D1 or D2) and are known as the D–J–C clusters. There are 13 J genes, designated J1S1 to J1S6 and J2S1 to J2S7.

The functional TCRγ genes are from 14 V segments and a duplicated J–C cluster consisting of three J genes (J1S1, J1S2, and J1S3) and one C gene, and two J genes (J2S1 and J2S3) and one C gene, respectively. The 14 V genes belong to four families. The TCRγV family consists of nine members, five of

Abbreviations: B-ALL, B cell acute lymphoblastic leukaemia; C, constant; CDR, complementarity determining regions; CMV, cytomegalovirus; CVID, common variable immunodeficiency; D, diversity; DOGE, denaturing gradient gel electrophoresis; EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; HLA, human major histocompatibility complex; HTLV, human T cell lymphotropic virus; Ig, immunoglobulin; IGL, large granular lymphocytosis; J, joining; MHC, major histocompatibility complex; MRD, minimal residual disease; PCR, polymerase chain reaction; PTCCL, peripheral T cell lymphoma; RSS, recombination signal sequences; RT, reverse transcription; SCID, severe combined immunodeficiency; SSCP, single strand conformation polymorphism; TCR, T cell receptor; TdT, terminal deoxynucleotidyl transferase; V, variable
which are functional and four of which are pseudogenes, and the remaining three families (II, III, and IV) each consist of a single gene. The remaining two genes are VA, which lies 5′ to the TCRGVII, and VB, which lies 5′ to TCRGVIII.

The TCRD locus is located within the TCRA locus between the AV and AJ gene segments. It is flanked by TCRD deleting elements (ιJA and δREC) such that rearrangements of the deleting elements to each other or rearrangement of AV to AJ gene segments causes deletion of the intervening TCRD gene locus. The germline encoded TCRD locus consists of eight V segments, three D segments, four J segments, and a single C segment.

V(D)J RECOMBINATION
The T lymphocyte has a unique ability to recognise a vast array of non-self antigens and rearrangement of multiple V, D, and J gene segments accounts for the diversity and specificity necessary for this function. During TCR gene rearrangement the V, D (only in TCRB and TCRD chain rearrangement), and J segments are brought together into a continuous V–D–J coding block (fig 2). These events are mediated by recombination activating genes, RAG1 and RAG2, and the enzyme terminal deoxynucleotidyl transferase (TdT). The TCR gene segments, as with the immunoglobulin genes, are flanked by recombination signal sequences (RSS), which act as recognition sites for the VDJ recombinase and mark the points at which somatic recombination occurs. The RSS comprises two conserved sequences, a heptamer (CACA/TGTG) separated by 12 or 23 random nucleotides from a consensus nonamer sequence (ACAAAAACC or GGTTTTTGT). Recombination may only take place between gene segments flanked by different spacers, and this phenomenon is known as the “12–23” rule. Therefore, V gene segments flanked 3′ by a 23 bp spacer can recombine with D segments or directly with J segments, both of which are flanked 5′ by a 12 bp spacer. The rearrangement of TCRB and TCRD is a two step process, in which a D gene first recombines with a J gene and then a V gene recombines with the D–J block (fig 2). Because of the absence of D genes in TCRA and TCRG, only V–J recombination occurs in these two chains.

“Diversity of the T cell repertoire is not only a consequence of different V, D, J recombinations but also results from nucleotide insertion and deletion at junctional sites”

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Genes encoding the T cell receptor (TCR) chains</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCR gene</td>
<td>Chromosome</td>
</tr>
<tr>
<td>α (A)</td>
<td>14q11–12</td>
</tr>
<tr>
<td>β (B)</td>
<td>7q32–35</td>
</tr>
<tr>
<td>γ (C)</td>
<td>7p15</td>
</tr>
<tr>
<td>δ (D)</td>
<td>14q11–12</td>
</tr>
</tbody>
</table>

C, constant; D, diversity; J, joining; V, variable.
During these recombination events, diversity at junctional regions is further increased by the incorporation of template dependent palindromic “P” nucleotides, incorporation of template independent GC rich “N” nucleotides by TdT, deletion of gene encoded nucleotides by exonucleolytic activity, and imprecise joining of gene segments. The junctional region (V(D)J) encodes the hypervariable CDR3. The CDRs (CDR1 and CDR2 within the V genes and CDR3 at the V(D)J junction) are regions of greatest sequence variability, which constitute the binding site for antigen with the CDR3 positioned at the centre of the antigen binding site for direct contact with the MHC bound peptide. Therefore, diversity of the T cell repertoire is not only a consequence of different V, D, J recombinations but also results from nucleotide insertion and deletion at junctional sites, thereby increasing diversity for recognition of a vast array of antigens. Furthermore, diversity is also created by the combinatorial association of individual TCRA and TCRB chains, and TCRG and TCRD chains. It is estimated that $10^{15}$ unique TCRs can be produced in this way.

**THE HUMAN T CELL REPERTOIRE**

There are several intrinsic and extrinsic factors that influence the expression of the TCR repertoire in humans. These include the human MHC (HLA) system and TCR gene polymorphisms, in addition to environmental factors, such as infection and superantigens. In normal individuals the T cell repertoire is stable and polyclonal. Whereas clonal populations are the hallmark of malignancy, clonal or oligoclonal populations of T and B cells may occur in non-malignant conditions including: human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) infections with specificity for virus, in the elderly, in autoimmunity, in common variable immunodeficiency (CVID), and in severe combined immunodeficiency (SCID), where RAG1 or RAG2 gene defects allow only a limited number of successful antigen receptor gene rearrangements, as occurs in patients with the Omenn’s SCID variant.

**ANALYSIS OF TCRB REPertoire**

**Phenotype: flow cytometric analyses**

Flow cytometry offers a quick, relatively inexpensive method of analysing the TCR repertoire, which is reproducible between laboratories and allows a quantitative evaluation of the expression of different V genes within different T cell subsets—that is, CD4+ and CD8+ cells. Whole blood can be analysed by three/four colour flow cytometry using fluorescently labelled monoclonal antibodies against TCRV family gene segments, together with anti-CD3 and anti-CD4 or anti-CD8 monoclonal antibodies. In particular, monoclonal antibodies now cover > 80% of the whole TCRV repertoire and reference values of the Vβ repertoire in healthy controls from different age groups are available. In contrast, only a few monoclonal antibodies recognise the Vα genes because of the vast number of TCRA V and J recombinations and the polymorphic nature of the α genes. TCRβ antibody studies can be used as an initial screening method for the detection of expanded families and/or skewing of the T cell repertoire in various disease states, including suspect T cell malignancies and proliferations, and immunodeficiency.

**Figure 2** T cell receptor β gene (TCRB) rearrangement. The RAG mediated recombination of the TCRB locus is a two step process in which a diversity (D) gene segment first recombines with a joining (J) segment, followed by the recombination of a variable (V) gene to the DJ block. The rearranged VDJ segment is then spliced post transcriptionally to the C transcript.
of the primers to template DNA. Furthermore, some primers to all gene segments because of the lack of homology from false negativity as a result of improper annealing of PCR DNA rely on family consensus primers and therefore suffer embedded, formalin fixed tissue. Many methods applicable to poor quality DNA extracted from paraffin wax RNA and RT-PCR, analysis of DNA is more common and ∼ and robust with good detection rates and sensitivity rates of (inverse PCR).

These last two methods are technically demanding but allow quantitative analysis of the T cell population. Such analyses have been applied to clonality studies in clinical pathology laboratories because of the restricted germline repertoire of the TCRG genes, which limits the number of required PCR primers. However, the limited repertoire also results in high background amplification of similar rearrangements in normal T cells. Furthermore, TCR gene rearrangements can be used as markers of clonality, not only in TCRβ positive malignancies (where the rearrangements are functional) but also in TCRδ positive malignancies, where non-functional TCRG gene rearrangements are seen as a consequence of the ordered hierarchy of TCR loci gene rearrangements.

Analysis of TCRD genes is mainly restricted to TCRβ positive malignancies, which are fairly rare, because the TCRD genes are deleted in most TCRβ positive T cell malignancies. However, the TCRD locus is extensively used as a target in minimal residual disease (MRD) detection in both T and B lineage acute lymphoblastic leukaemia (ALL), particularly because cross lineage TCRD gene rearrangements occur extensively in precursor B cell ALL (B-ALL). The TCRD is a useful target as a result of the combination of three factors, namely: (1) limited germline repertoires, (2) specific recombination patterns in different subtypes of ALL, and (3) extensive junctional diversity.

Genotype: PCR methods
The advent of the polymerase chain reaction (PCR) technique has largely replaced Southern blot analysis for clonality studies because PCR offers several advantages, with the principal being that it is quicker to perform and poor quality DNA can be used. The type of PCR approach will depend on whether DNA or RNA based methods are applicable. Paraffin wax embedded material is often the only material available in routine diagnostic pathology laboratories, so protocols are restricted to DNA based methods and the amplification of small (< 250 bp) PCR fragments. Both DNA and RNA methods are suitable for fresh material.

Reverse transcription PCR (RT-PCR) using RNA can be used for the analysis of the expressed TCR repertoire. Suitable PCR methods include: (1) amplification of all V segments using family specific primers complementary to all TCRV genes and a constant region primer (although easy and reliable, this method at best can only provide a semiquantitative profile of TCRV usage); (2) modification of all TCR transcripts so that they can be amplified by one oligonucleotide (anchor PCR); and (3) the production of circular transcripts by ligation (inverse PCR). These last two methods are technically demanding but allow quantitative analysis of the T cell population. Such analyses have been applied to clonality studies and the evaluation of the TCR repertoire in immunodeficiency, autoimmune disease, and alloreactive T cells in allografts.

Methods for routine clonality assessment should be simple and robust with good detection rates and sensitivity rates of ~5%. Although clonality assessment can be completed using DNA and RT-PCR, analysis of DNA is more common and applicable to poor quality DNA extracted from paraffin wax embedded, formalin fixed tissue. Many methods applicable to DNA rely on family consensus primers and therefore suffer from false negativity as a result of improper annealing of PCR primers to all gene segments because of the lack of homology of the primers to template DNA. Furthermore, some

approaches have used nested PCR, which may suffer from contamination problems. Presently, a European project (BIOMED-2 concerted action (PL-96–3936)) is trying to deal with the problem of false negatives common to all PCR protocols. The project has involved the design of new and specific primers for all TCR and immunoglobulin (Ig) loci and the standardised testing of all cases. This approach has already increased detection rates and sensitivity.

PCR analysis of the TCRG genes is the protocol mostly widely applied to clonality studies in clinical pathology laboratories because of the restricted germline repertoire of the TCRG genes, which limits the number of required PCR primers. However, the limited repertoire also results in high background amplification of similar rearrangements in normal T cells. Furthermore, TCRG gene rearrangements can be used as markers of clonality, not only in TCRβ positive malignancies (where the rearrangements are functional) but also in TCRδ positive malignancies, where non-functional TCRG gene rearrangements are seen as a consequence of the ordered hierarchy of TCR loci gene rearrangements.

Analysis of TCRD genes is mainly restricted to TCRβ positive malignancies, which are fairly rare, because the TCRD genes are deleted in most TCRβ positive T cell malignancies. However, the TCRD locus is extensively used as a target in minimal residual disease (MRD) detection in both T and B lineage acute lymphoblastic leukaemia (ALL), particularly because cross lineage TCRD gene rearrangements occur extensively in precursor B cell ALL (B-ALL). The TCRD is a useful target as a result of the combination of three factors, namely: (1) limited germline repertoires, (2) specific recombination patterns in different subtypes of ALL, and (3) extensive junctional diversity.

“PCR analysis of the TCRG genes is the protocol mostly widely applied to clonality studies in clinical pathology
The restricted germline repertoire of the TCRG genes, which limits the number of required PCR primers, makes the TCRB locus the locus of choice for establishing clonality of TCRαβ expressing tumours, which comprise more than 90% of lymphoid malignancies. DNA based methods have exploited the extensive TCRB germline repertoire with varied success. However, recently family specific BV primers have been applied to DNA as part of the BIOMED-2 programme and have achieved improved detection rates for TCRB clonality. The TCRA locus has proved too complex for suitable DNA clonal analyses.

**Detection systems**

TCR PCR fragments may be detected in a variety of ways to discriminate the junctional diversity between polyclonal and clonal populations. These methods include fluorescent gene scanning, heteroduplex analysis, single strand conformation polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), cloning, and sequencing.

Fluorescent gene scanning involves the amplification of specific TCR genes using fluorescently labelled primers. Such analysis is used in routine clonality assessment of TCRG and TCRB genes, TCRBV family usage, and MRD studies. The resulting PCR products are run on a gene sequencer and analysed using GeneScan software (Applied Biosystems, Warrington, Cheshire, UK). Polyclonal populations with varying PCR fragment lengths demonstrate a normal Gaussian distribution visualised as a series of peaks. Clonal populations are seen as distinct peaks (fig 4).

Heteroduplex analysis (and the less frequently used SSCP analysis), rely on conformational changes caused by mismatch at the junctional region visualised by retardation on a gel matrix. True clonal PCR products give rise to homoduplexes, whereas polyclonal PCR products form heteroduplexes upon renaturation. Because of differences in conformation, the clonal homoduplexes (PCR products with identical junctional regions from clonal populations) migrate more rapidly through the gel and are seen as intense clonal bands, whereas heteroduplexes with less perfectly matched sequences (PCR products with heterogeneous junctional regions) appear as ill defined smears running behind the homoduplex (fig 4). DGGE allows rapid screening for single base changes at the CDR3 region. This technique is based on the migration of double stranded DNA through a polyacrylamide gel containing increasing concentrations of a denaturing agent.

Cloning and sequencing provides perhaps the best method of assessing clonality within T cell populations, allowing a...
been found. Gene rearrangements are usually restricted to the Ig heavy neoplasms (ALL) than mature neoplasms. Rearrangements are more common among immature lymphoid (VDJ or VJ) rearrangements. Furthermore, cross lineage recombination, but which do not reflect the final lineage commitment of the tumour cells. Approximately 25–30% of high grade lymphoblastic B cell malignancies

<table>
<thead>
<tr>
<th>Disease</th>
<th>T cell receptor</th>
<th>Immunoglobulin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TCRB</td>
<td>TCRG</td>
</tr>
<tr>
<td>Lymphoblastic T cell malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD3− T ALL</td>
<td>84</td>
<td>85</td>
</tr>
<tr>
<td>CD3+ T ALL</td>
<td>96</td>
<td>100</td>
</tr>
<tr>
<td>Lymphoblastic T NHL</td>
<td>79</td>
<td>100</td>
</tr>
<tr>
<td>Mature T cell malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T CLL</td>
<td>84</td>
<td>97</td>
</tr>
<tr>
<td>T PLL</td>
<td>100</td>
<td>90</td>
</tr>
<tr>
<td>ATLL</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Peripheral T NHL</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>CTL/MF</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>lymphoblastic B cell malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Null ALL</td>
<td>9</td>
<td>22</td>
</tr>
<tr>
<td>Common ALL</td>
<td>41</td>
<td>66</td>
</tr>
<tr>
<td>Prec B ALL</td>
<td>23</td>
<td>44</td>
</tr>
<tr>
<td>B ALL</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mature B cell malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B CLL</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>HCL</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>B NHL</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>5</td>
<td>0</td>
</tr>
</tbody>
</table>

Table adapted from van Dongen and Wolvers-Tettero\(^7\) and Gill and Guller\(^9\).

The molecular diagnosis of non-Hodgkin’s lymphoma and leukaemias is based on the fact that all cells have a common clonal origin and > 98% of cases exhibit clonal rearrangements of TCR and Ig genes, reflecting their cellular origins from T or B cells, respectively.\(^7\) Molecular analyses are extremely helpful for diagnosis in cases with unusual morphological features, confusing immunophenotypic characteristics, or where a phenotypic clonal marker is lacking. Nevertheless, it should be remembered that the presence of clonal gene rearrangements does not necessarily imply malignancy because several benign or reactive inflammatory conditions may show such a pattern. Some examples include benign inflammatory disorders of skin, such as lymphomatoid papulosis and pityriasis lichenoides et varioliformis acuta, where clonal T cell expansions are evident.\(^9,91–93\) Conversely, the absence of a clonal gene rearrangement does not rule out malignancy because the population of malignant cells may be at a level below the sensitivity of the technique. The current consensus view is that lymphomas can only be defined by a combination of clinical, histological, and immunological data.\(^9,94\)

Table 2 shows the incidence of clonal rearrangements in lymphoproliferative disorders. At our centre, 60% of all lymphoproliferations referred for clinical investigations are suspect T cell lymphoproliferations, and more than 65% of these specimens are referred as formalin fixed, paraffin wax embedded biopsies. Two problematical areas of diagnosis include lymphoproliferations in skin and peripheral T cell lymphoma (PTCL).

More than 25% of referrals to our laboratory are skin lymphoproliferations. The diagnosis of lymphoproliferations in skin is a difficult task, because lymphoid infiltrates with similar histological features may represent widely disparate clinical diseases. Conversely, the histological picture associated with certain diagnoses such as mycosis fungoides can vary greatly between individuals and at different times in the clinical course of the disease. TCR and clonality studies have proved to be of immense help in the diagnosis and follow up of patients with cutaneous T cell lymphomas.\(^9,95\)

The interpretation of clonality in PTCL can also be difficult, especially those of the angioimmunoblastic type (AILD), where the interpretation of clonality is complicated by the heterogeneity of TCR and IgR rearrangements. In addition, clonal rearrangements have been shown to regress or appear during the course of disease, suggesting that these cases harbour multiple clones similar to those found in cases with acquired immunosuppression. Although most cases exhibit TCR rearrangements, we have recently shown that functional T and B cell oligoclonal antibodies can be found in up to 30% of cases.\(^9,96\)

The molecular diagnosis of non-Hodgkin’s lymphoma and leukaemia is based on the fact that all cells have a common clonal origin and > 98% of cases exhibit clonal rearrangements of TCR and Ig genes, reflecting their cellular origins from T or B cells, respectively.\(^7\) Molecular analyses are extremely helpful for diagnosis in cases with unusual morphological features, confusing immunophenotypic characteristics, or where a phenotypic clonal marker is lacking. Nevertheless, it should be remembered that the presence of clonal gene rearrangements does not necessarily imply malignancy because several benign or reactive inflammatory conditions may show such a pattern. Some examples include benign inflammatory disorders of skin, such as lymphomatoid papulosis and pityriasis lichenoides et varioliformis acuta, where clonal T cell expansions are evident.\(^9,91–93\) Conversely, the absence of a clonal gene rearrangement does not rule out malignancy because the population of malignant cells may be at a level below the sensitivity of the technique. The current consensus view is that lymphomas can only be defined by a combination of clinical, histological, and immunological data.\(^9,94\)

Table 2 shows the incidence of clonal rearrangements in lymphoproliferative disorders. At our centre, 60% of all lymphoproliferations referred for clinical investigations are suspect T cell lymphoproliferations, and more than 65% of these specimens are referred as formalin fixed, paraffin wax embedded biopsies. Two problematical areas of diagnosis include lymphoproliferations in skin and peripheral T cell lymphoma (PTCL).

More than 25% of referrals to our laboratory are skin lymphoproliferations. The diagnosis of lymphoproliferations in skin is a difficult task, because lymphoid infiltrates with similar histological features may represent widely disparate clinical diseases. Conversely, the histological picture associated with certain diagnoses such as mycosis fungoides can vary greatly between individuals and at different times in the clinical course of the disease. TCR and clonality studies have proved to be of immense help in the diagnosis and follow up of patients with cutaneous T cell lymphomas.\(^9,95\)

The interpretation of clonality in PTCL can also be difficult, especially those of the angioimmunoblastic type (AILD), where the interpretation of clonality is complicated by the heterogeneity of TCR and IgR rearrangements. In addition, clonal rearrangements have been shown to regress or appear during the course of disease, suggesting that these cases harbour multiple clones similar to those found in cases with acquired immunosuppression. Although most cases exhibit TCR rearrangements, we have recently shown that functional T and B cell oligoclonal antibodies can be found in up to 30% of cases.\(^9,96\)

Our data do not support the concept of AILD as a clearly defined PTCL, but offer experimental evidence in support of the observation of Lipford et al.,\(^7\) who concluded that AILD is a disease of proliferating lymphoid clones in which supervening malignant lymphomas may develop by a process of clonal selection. Figure 4 shows a malignant T cell proliferation as detected by heteroduplex analysis and fluorescent gene scanning.

---

**THE DIAGNOSTIC ROLE OF TCR GENE REARRANGEMENT STUDIES**

**T cell lymphomas and leukaemias**

The molecular diagnosis of non-Hodgkin’s lymphoma and leukaemia is based on the fact that all cells have a common clonal origin and > 98% of cases exhibit clonal rearrangements of TCR and Ig genes, reflecting their cellular origins from T or B cells, respectively.\(^7\) Molecular analyses are extremely helpful for diagnosis in cases with unusual morphological features, confusing immunophenotypic characteristics, or where a phenotypic clonal marker is lacking. Nevertheless, it should be remembered that the presence of clonal gene rearrangements does not necessarily imply malignancy because several benign or reactive inflammatory conditions may show such a pattern. Some examples include benign inflammatory disorders of skin, such as lymphomatoid papulosis and pityriasis lichenoides et varioliformis acuta, where clonal T cell expansions are evident.\(^9,91–93\) Conversely, the absence of a clonal gene rearrangement does not rule out malignancy because the population of malignant cells may be at a level below the sensitivity of the technique. The current consensus view is that lymphomas can only be defined by a combination of clinical, histological, and immunological data.\(^9,94\)

Table 2 shows the incidence of clonal rearrangements in lymphoproliferative disorders. At our centre, 60% of all lymphoproliferations referred for clinical investigations are suspect T cell lymphoproliferations, and more than 65% of these specimens are referred as formalin fixed, paraffin wax embedded biopsies. Two problematical areas of diagnosis include lymphoproliferations in skin and peripheral T cell lymphoma (PTCL).

More than 25% of referrals to our laboratory are skin lymphoproliferations. The diagnosis of lymphoproliferations in skin is a difficult task, because lymphoid infiltrates with similar histological features may represent widely disparate clinical diseases. Conversely, the histological picture associated with certain diagnoses such as mycosis fungoides can vary greatly between individuals and at different times in the clinical course of the disease. TCR and clonality studies have proved to be of immense help in the diagnosis and follow up of patients with cutaneous T cell lymphomas.\(^9,95\)

The interpretation of clonality in PTCL can also be difficult, especially those of the angioimmunoblastic type (AILD), where the interpretation of clonality is complicated by the heterogeneity of TCR and IgR rearrangements. In addition, clonal rearrangements have been shown to regress or appear during the course of disease, suggesting that these cases harbour multiple clones similar to those found in cases with acquired immunosuppression. Although most cases exhibit TCR rearrangements, we have recently shown that functional T and B cell oligoclonal antibodies can be found in up to 30% of cases.\(^9,96\)

Our data do not support the concept of AILD as a clearly defined PTCL, but offer experimental evidence in support of the observation of Lipford et al.,\(^7\) who concluded that AILD is a disease of proliferating lymphoid clones in which supervening malignant lymphomas may develop by a process of clonal selection. Figure 4 shows a malignant T cell proliferation as detected by heteroduplex analysis and fluorescent gene scanning.
"The presence of clonal gene rearrangements does not necessarily imply malignancy because several benign or reactive inflammatory conditions may show such a pattern."

During the treatment of many haematological malignancies, tumour cells may become undetectable in blood, bone marrow, etc by conventional means. However, many cases may still relapse, indicating that biological remission has not been achieved. MRD describes the presence of tumour cells at a level below that detectable by conventional methodology and provides accurate information about the efficacy of treatment regimens. Furthermore, MRD analysis can predict outcome by determining malignant cell burden during initial treatment. Most MRD assays use "real time" technology to quantify specific PCR products. Using this technique, the PCR product is measured at each cycle by cleavage of a fluorescent intrinsic probe by the emission of a fluorescent signal that accumulates during the reaction. Because post-PCR processing is not necessary, quantitative data can be accumulated quickly. Real time primers and probes have been applied to patient specific junctional regions in ALL, in addition to BCR-ABL fusion transcripts in chronic myeloid leukaemia, to provide accurate and reliable data for MRD detection.

Large granular lymphocytes

The syndrome of large granular lymphocytosis (LGL) with chronic neutropenia was recognised as a distinct clinical entity in 1977. Two types of LGLs have been described on the basis of their lineages: CD3+ LGL and CD3− LGL. Whereas CD3+ LGLs express and rearrange TCRs, CD3− LGLs are composed of natural killer cells which do not rearrange their TCR or Ig genes. Although clonality can be easily demonstrated in the more common CD3+ LGL by the detection of TCR gene rearrangement, clonality is less easy to demonstrate in CD3− LGL, although clonal analysis using the lineage independent method of X inactivation has been applied to this group. Furthermore, the detection of a single episomal form of EBV has been used as evidence that the LGL has arisen from a single EBV infected cell.

One of the key questions in this disorder has been whether LGL represents a "reactive" or "neoplastic" proliferation. It should also be noted that oligoclonal/clonal T cell expansions are frequently seen in the peripheral blood of normal healthy individuals. Such expansions are most prominent among CD8+ T cells and are increasingly present with age, being detectable in adults (> 35 years of age) and becoming very frequent in the elderly (> 70 years of age). However, such populations are not known in the young. We have recently described two paediatric cases presenting in the 2nd decade of life with neutropenia and sepsis. Both cases had expanded clonal populations of TCRBV13 CD8+ T cells. Both patients received cyclosporin and showed pronounced clinical improvement. In contrast, the CD4+ T cell repertoire remains largely polyclonal throughout life, although expanded CD4+/CD45RO+ populations have been detected in elderly individuals.

Although some reports have highlighted that clonality studies and CD8 TCRBV family profiling are useful in monitoring disease progression and response to treatment in LGL, it has been suggested that the morbidity and mortality in LGL is primarily related to neutropenia rather than lymphocytosis. Most of our current knowledge regarding the management of these patients comes from anecdotal case reports and with the uncertainty in the diagnosis, the indication for beginning aggressive immunosuppressive treatment remains unclear.

Infection

Infections, particularly viral (EBV, cytomegalovirus (CMV), human T cell lymphotropic virus (HTLV), and HIV) and staphylococcal toxic shock syndrome, are known to induce lymphocytosis, usually polyclonal, but occasionally clonal. The lymphocytoses in CMV, EBV, and HTLV infection are usually associated with an expansion of LGLs. After EBV infection, memory clonotypic CD8+ cells persist at relatively high circulating frequencies and are necessary for maintaining a balanced host-virus relationship in normal individuals. More recently, oligoclonality has also been seen in hepatitis B virus specific CD8+ cells using HLA-A2 peptide tetramers.

EBV is commonly associated with post transplant lymphoproliferative disease of oligoclonal B cell origin. T cell proliferations after transplantation are uncommon but such populations have been reported. Reactive oligoclonal populations can also occur following transplantation that represent re-population of the bone marrow, and which cannot be interpreted as re-occurrence of malignancy without reference to the original clone.

TCR family expansions have also been reported in HIV positive patients with low CD4+ cell counts, and it has been suggested that the virus per se may have a superantigen effect on the TCR. Recent studies have also shown that in the early phases of HIV infection there is a transient expansion of CD8+ T cells, which in some patients may persist for six to 30 months. CD8+ T cells play an important role in protection and control of HIV-1 by direct cytolysis of infected cells and by suppression of viral replication by secreting cytokines, chemokines, and CD8+ T cell antiviral factors. Although clonality and oligoclonality can be demonstrated in a proportion of these cells they represent a reactive expansion of CD8+ T cells rather than malignancy. A decline in reactive clonal CD8 cells has been linked to progression to AIDS, with a strong inverse correlation between the in vivo frequency of HIV specific clones and levels of viraemia.

Immunodeficiency

In many primary immunodeficiencies a high degree of clonality/oligoclonality is present within lymphocyte populations. Restricted heterogeneity of T cell subpopulations has been described in Omenn’s syndrome, with skewing of the TCRBV repertoire and the presence of oligoclonal T cell populations. Omenn’s syndrome was first described in 1965 as a severe form of SCID, characterised by erythromeda, failure to thrive, and lymphadenopathy. High numbers of activated, anergic T cells are usually present and infiltrate skin and gut epithelium. Recent reports have described mutations in RAG1 and RAG2 genes in this syndrome. However, clinically defined Omenn’s syndrome may be a more complex entity than is currently recognised. We have recently studied eight children with clinically defined Omenn’s syndrome and identified eight of the eight demonstrated RAG gene mutations. Analyses of the TCRBV repertoire were seen with five of the eight children demonstrating oligoclonal TCRV gene rearrangements. Although failure to demonstrate TCRBV clonality may arise from the lack of homology of V primers to all known V genes, these results suggest that TCRBV skewing and clonality may not be seen in all cases and may, in part, be related to the type of RAG gene mutation. Furthermore, oligoclonal B cell populations found in one child in the absence of clonal T cells were confirmed by gene sequencing (J L Smith et al, unpublished data, 2002). Such data suggest that Omenn’s syndrome is a more heterogeneous disease than previously recognised.

The differentiation of materno–fetal graft versus host disease from Omenn’s syndrome in patients with SCID and similar presenting features can be resolved by chimaerism studies. Although materno–foetal grafts have not been
Clonality in autoimmunity and atopy

In many autoimmune and atopic disorders localised T cell expansions have been described in the affected tissue and subsequent clonality studies have identified increased oligoclonality within T cells at these sites. In both rheumatoid arthritis and multiple sclerosis, various different TCRAV and TCRBV segments have been found to be expanded, and oligoclonal/clonal populations of CD4+ and CD8+ T cells have been identified at the disease sites.65 79 93 100 116; however, no consistent usage of TCRBV families has been identified between studies. Some of these studies have implications for immunotherapy.110

Clonal and oligoclonal lymphocyte expansions can be found in the lungs of atopic and non-atopic patients with asthma and normal individuals.119 Therefore, it is difficult to comment on the clinical relevance of these findings; however, clonal populations can also be found after allergen challenge, suggesting a specific T cell response in some cases. Although the lung T cell repertoire is broadly representative of blood T cells, there does appear to be selection and amplification of specific T cell families in the lung in response to local antigenic stimulation.114 115 In a recent study, we examined the clonality of the T cell response to peanut in MHC class II identical peanut allergy discordant siblings. In vitro stimulation of peripheral blood mononuclear cells with crude peanut extract resulted in stimulation of clonal/oligoclonal T cell responses, together with increased usage of TCRBV11 in peanut allergic individuals.118

Analysis of clonality is a further means of characterising T cells in clinical hypersensitivity reactions; however, apparent specific T cell responses to antigen in some atopic individuals, characterised by oligoclonality of T cell populations at the affected site, do not always provide unique clonality profiles that could be used as diagnostic markers for these diseases.

CONCLUSION

Advances in molecular biological techniques have provided a variety of methods for the investigation of disease. Methods are applicable to RNA and DNA, including poor quality DNA isolated from paraffin wax embedded biopsy material, thus enabling retrospective analyses to be carried out. Foremost among these applications is the diagnosis of lymphocytic disease and differentiation from reactive lymphoproliferations. These applications are less well defined for patient monitoring but are useful for monitoring MRD and in patients with CD8+ lymphocytoses. Methods based on real time PCR are also available for monitoring MRD after treatment or bone marrow transplantation. The study of the T cell repertoire has proved diagnostically useful for the definition of immunodeficiency states, most notably, Omenn’s syndrome.

T cell receptor (TCR) gene rearrangement is an important event in T cell ontogeny that enables T cells to recognise antigens specifically, and any dysregulation in this process may result in disease. Techniques such as Southern blot hybridisation, polymerase chain reaction (PCR), and flow cytometry have enabled T cell proliferations to be characterised in malignancy and in diseases where T cells have been implicated in the pathogenesis, such as immunodeficiency, autoimmunity, and atopy. One of the most important of these applications is the diagnosis of lymphocytic disease and its differentiation from reactive lymphoproliferations.

These applications are less well defined for patient monitoring but are useful for monitoring minimal residual disease (MRD) and in patients with CD8+ lymphocytoses. Methods based on real time PCR are also available for monitoring MRD after treatment or bone marrow transplantation. TCR gene studies have been diagnostically useful for the definition of immunodeficiency states, most notably, Omenn’s syndrome, and for the characterisation of T cells at disease sites in patients with autoimmune disease or allergy. However, PCR technology has a high incidence of false negativity, resulting from the use of consensus primers, so that several groups are working towards the design of better primers.

Although clonal rearrangements are the hallmark of lymphoid tumours, monoclonal proliferations have been reported in patients with CVID without progression. The most common type of primary immunodeficiency in clinical practice is CVID. Significant differences in TCRBV gene usage has been reported in patients with CVID, and in particular those with an associated CD8+ lymphocytosis. Up to 15% of patients with CVID have lymphadenopathy, with granulomatous lymphadenopathy occurring in 75% of all biopsies. The remainder, including reactive and atypical lymphoid hyperplasia, lack distinctive features and in these patients prediction of clinical outcome is highly unsatisfactory. Lymphomas occurring in patients with CVID are usually diffuse and are of intermediate or high grade in the working formulation. The diagnosis is complicated by the fact that lymphoid tissue from all patients with CVID can be histologically abnormal because germinal centres are frequently absent or poorly developed, so that stimulation by infection can result in histologies that are difficult to differentiate from lymphoma. Lymphomas of B cell type predominate in CVID, although T cell types have been reported. The interpretation of clonality in this group of patients is complex. Although clonal rearrangements are the hallmark of lymphoid tumours, monoclonal proliferations have been reported in patients without progression. In a recent UK study, we have reviewed clonality in biopsies of reactive and lymphoma histologies. Although clearly present in lymphoma tissue, clonal populations of B cells were also found in reactive biopsies and biopsies of equivocal lymphoma histology. Apparent clonality may result from small numbers of B cells present in some biopsies, but this was not true in all biopsies of reactive histology. In CVID, clonal populations cannot be definitive for lymphoma and these findings must be interpreted with the immunohistology of the biopsy and the clinical presentation of the patient.
and for the characterisation of T cells at disease sites in patients with autoimmune disease or allergy. Nevertheless, one of the limitations of PCR technology is the high incidence of false negativity, resulting from the use of conserved primers. Currently, there are several groups working towards the design of better primers, which we hope will be available in forthcoming years.

References

C. References

Author’s affiliations

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.

E. Hodges, M. T. Krishna, C. Pickard, J. L. Smith, Wessex Immunology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK.
ECHO

Tumour suppressor genes do not regulate the cell cycle

A study of the effects of hamartin and tuberin on cell growth suggests that tuberin acts as a tumour suppressor gene—indeed not by regulating the cell cycle, but by inducing transient overexpression of hamartin and tuberin in cell cultures from a human kidney (HEK293) cell line by transfection. They used constructs of the TSC1 gene for hamartin and TSC2 gene for tuberin to transfected the cultures, separately and together, and constructs for three common TSC2 mutants. They measured cell growth with two colour fluorescence activated cell sorting to analyse the percentage of cells in each growth phase.

TSC2, alone or with TSC1, produced a significant increase in G1 phase cells (41%, 39%) over the vector control (32%). So did a TSC2 mutation in exon 16 or 38 but not a C-terminus truncation mutation (41%, 40%, and 33%, respectively). TSC1 did not alter the percentage of G1 phase cells.

When the cultures were grown with nocodazole to block the cell cycle at phase G2/M, those with TSC2, with or without TSC1, still showed a significant increase in cells in G1 (14%, 17%, respectively). Cultures with a TSC2 exon mutation behaved similarly (17%, 13%), but with TSC1 and the C-terminus TSC2 mutation G1 phase cells remained low.

TSC1 and TSC2 mutations cause tuberous sclerosis complex (TSC), with widespread tumours, including kidney tumours, and seizures and autism. Until now, both wild type genes were believed to act together as tumour suppressors, but the mechanism is unknown. 